Dyadic International ( (DYAI) ) has shared an announcement.
On March 20, 2025, Dyadic International announced a $4.5 million funding award from CEPI to accelerate the development of protein-based vaccines using its C1 fungus technology. The initiative aims to reduce vaccine development timelines significantly, potentially enabling vaccines to enter Phase 1 trials in just 35 days compared to the traditional four to six months. This approach could also lower production costs and increase accessibility, particularly in regions with less established manufacturing infrastructure, aligning with the global 100 Days Mission to expedite vaccine readiness against pandemic threats.
More about Dyadic International
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness. The company utilizes its proprietary C1-cell protein production platform to speed development, lower production costs, and improve performance of biologic vaccines and drugs.
YTD Price Performance: -18.05%
Average Trading Volume: 84,063
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $40.83M
For a thorough assessment of DYAI stock, go to TipRanks’ Stock Analysis page.